• Explore /
  • Poster
  • / Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.

Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.

Abstract Poster

Authors

null

Shaan Dudani

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Shaan Dudani , Chun Loo Gan , Connor Wells , Ziad Bakouny , Nazli Dizman , Sumanta K. Pal , Lori Wood , Christian K. Kollmannsberger , Bernadett Szabados , Thomas Powles , Benoit Beuselinck , Frede Donskov , Aaron Richard Hansen , Georg A. Bjarnason , Christina M. Canil , Sandy Srinivas , Neeraj Agarwal , Elizabeth Chien Hern Liow , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5063)

DOI

10.1200/JCO.2020.38.15_suppl.5063

Abstract #

5063

Poster Bd #

132

Abstract Disclosures

Similar Posters

First Author: Audreylie Lemelin

First Author: Esmail Mutahar Al-Ezzi

First Author: Yu Fujiwara

First Author: Neil J. Shah